- After 11 years in the position
- Praise and thanks for Rogers
- Search for a successor
- Rogers said 81 words
(exechange) — Sunnyvale, California, October 10, 2023 — This news came shortly after Columbus Day. Erica Rogers, chief executive of Silk Road Medical, leaves her position. As announced by Silk Road Medical Inc. in a news release and in a regulatory filing published on Tuesday, October 10, 2023, Erica J. Rogers leaves her post as chief executive officer at the medical device company, after 11 years in the role, effective when her successor is appointed.
Silk Road Medical will undertake a search for a successor.
The planned management change is explained as follows. Silk Road Medical stated: “Ms. Rogers’s plans to retire are for personal reasons and not because of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
Precise information regarding Erica Rogers’s future plans was not immediately available.
Silk Road Medical said: “CEO Erica Rogers plans to retire from the Company following the completion of a succession process.”
Silk Road Medical further said: “On October 10, 2023, after serving as the Company’s President and Chief Executive Officer (“CEO”) for over 11 years, Erica J. Rogers informed the Company and its Board of Directors (the “Board”) of her plans to retire from the Company following the completion of a succession process.”
Share price decline since October 2020
The announcement follows a decline in Silk Road Medical Inc.’s share price of 78% since October 2020.
In the position of CEO since 2012
Erica Rogers became CEO of the Company in 2012.
Rogers has served as the Company’s President and Chief Executive Officer and a member of the Company’s board of directors since October 2012.
Rogers previously served as Chief Operating Officer of Medicines360, a non-profit pharmaceutical company developing drugs and devices for women, from June 2010 to October 2012.
Rogers was an Executive Vice President at Nanosys, Inc. from December 2008 to March 2010.
Prior to that, Rogers founded and was Chief Executive Officer of Allux Medical, and co-founded Visiogen, which was acquired by Abbott Medical Optics in 2009.
She worked previously in neurovascular marketing at Target Therapeutics and peripheral vascular sales and sales training at Boston Scientific.
Rogers served on the board of directors of Lucira Health, Inc., a publicly traded medical diagnostics company, from November 2020 through September 2022, and currently serves on the board of directors of Sight Sciences, Inc. a publicly traded device company, since 2019, and for HistoSonics, Inc., a privately held medical device company since December 2022.
Rogers received a B.S. in zoology from San Diego State University.
81 words by Erica Rogers
In the release announcing her departure as CEO of Silk Road Medical Inc., Erica Rogers received praise and thanks.
In announcing her departure, Erica Rogers said 81 words.
“Supporting a smooth transition and cheering on our team”
Erica Rogers stated: “It has been an honor to work with the Silk Road team through more than a decade of progress toward improving patients’ lives. I’m incredibly proud of the foundation we’ve built, our amazing employees, and our undeniable leadership in carotid artery disease innovation. We have set the stage for an exciting future for the Company. I look forward to supporting a smooth transition and cheering on our team as they continue to promote TCAR as the gold standard in stroke prevention.”
Push-out Score for Erica Rogers’s move determined
The Push-out Score indicates on a scale of 0 to 10 how likely it is that Erica Rogers was pushed out or felt pressure to leave her position.
exechange reached out to Silk Road Medical and offered the company the opportunity to comment on the score.
Read the full story in the exechange report 42.2023 ($).